Adaptive Biotechnologies Stock Price, News & Analysis

Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotechnology company focused on adaptive immune system genetics, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL. The company's management will engage in a fireside chat on June 11th at 5:40 a.m. PT / 8:40 a.m. ET. Investors and interested parties can access both live and archived webcasts of the presentation through the company's website investor section at www.adaptivebiotech.com.

Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotechnology company focused on translating adaptive immune system genetics into clinical products, has scheduled its Q1 2025 financial results announcement for May 1, 2025, after market close.

The company will host a conference call and webcast at 1:30 PM Pacific Time / 4:30 PM Eastern Time on the same day. Investors can access the live audio webcast through the company's website investor section, with a replay available within 24 hours after the event.

Adaptive Biotechnologies (Nasdaq: ADPT) has secured expanded Medicare coverage for its clonoSEQ® test in mantle cell lymphoma (MCL) surveillance. The coverage now includes single time point testing to monitor disease recurrence in patients during treatment-free remission.

Under the expanded coverage by Palmetto GBA, patients who have completed treatment can receive clonoSEQ testing every six months for up to five years during treatment-free remission, followed by annual testing until disease recurrence. The test pricing is set at $2,007 per test under the Clinical Laboratory Fee Schedule.

MCL, affecting approximately 4,000 new cases annually in the United States, is the first clonoSEQ indication to receive this coverage determination. The test is performed at Adaptive's CLIA-certified lab in Seattle and has received approval from New York State's Clinical Laboratory Evaluation Program.

Adaptive Biotechnologies (NASDAQ: ADPT) has launched an enhanced version of its clonoSEQ assay for measuring residual disease (MRD) in diffuse large B-cell lymphoma (DLBCL) using circulating tumor DNA. The upgraded assay delivers a 7-fold increase in sensitivity while maintaining high specificity to minimize false positives.

The enhanced version received approval from New York State's Clinical Lab Evaluation Program (CLEP) and is the only DLBCL MRD assay available for clinical use with Medicare coverage. Since securing Medicare coverage in July 2022, clonoSEQ has been used to test over 2,800 DLBCL patients and was utilized by more than 640 providers in 2024.

DLBCL, affecting over 18,000 new patients annually, is the most common form of non-Hodgkin lymphoma, representing one-third of NHL cases. With 30-40% of patients experiencing relapse, the enhanced MRD testing capabilities help doctors assess treatment response and detect early cancer recurrence signs.

Adaptive Biotechnologies (ADPT) reported Q4 and full year 2024 financial results, showing mixed performance. Q4 revenue reached $47.5 million (+4% YoY), with MRD business contributing 85% of revenue and growing 31% YoY to $40.1 million. Full-year revenue was $179.0 million (+5% YoY), with MRD revenue up 42% to $145.5 million.

The company's clonoSEQ test volume increased 34% to 20,945 tests in Q4 2024, with 76,105 tests delivered in 2024 (+35% YoY). Medicare increased the Clinical Laboratory Fee Schedule rate for clonoSEQ by 17% to $2,007 per test.

Q4 net loss improved to $33.7 million from $69.5 million in Q4 2023. Full-year 2024 net loss was $159.6 million, compared to $225.3 million in 2023. Cash position stood at $256.0 million as of December 31, 2024.

For 2025, ADPT expects MRD business revenue between $175-185 million and total operating expenses of $340-350 million, with projected cash burn of $60-70 million.

Adaptive Biotechnologies (Nasdaq: ADPT) has announced its participation in two upcoming investor conferences. The company, which specializes in translating adaptive immune system genetics into clinical products, will attend the BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT on February 12, 2025, and the TD Cowen 45th Annual Health Care Conference in Boston, MA on March 3, 2025.

At the TD Cowen conference, the company will participate in a fireside chat scheduled for 11:10 a.m. Eastern Time. Investors and interested parties can access live and archived webcasts of the sessions through the 'Investors' section of Adaptive Biotechnologies' website at www.adaptivebiotech.com.

Adaptive Biotechnologies (Nasdaq: ADPT) has announced it will release its fourth quarter and full year 2024 financial results after market close on Tuesday, February 11, 2025. The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results. Investors can access the live audio webcast through the company's website, and a replay will be available within 24 hours after the event.

Adaptive Biotechnologies (ADPT) and NeoGenomics (NEO) announced a multi-year exclusive strategic commercial collaboration to enhance minimal residual disease (MRD) monitoring for blood cancer patients. The partnership integrates Adaptive's FDA-cleared clonoSEQ test with NeoGenomics' COMPASS and CHART assessment services.

The collaboration enables clinicians using NeoGenomics' COMPASS for initial blood cancer diagnosis to simultaneously identify DNA sequences for patient tracking. The service covers multiple myeloma, B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma. Subsequent CHART assessments can include clonoSEQ MRD testing throughout treatment.

Testing will be performed at Adaptive's CLIA-certified, CAP-accredited laboratory in Seattle. The companies will begin implementing the necessary infrastructure with cross-promotional efforts expected later this year. Financial terms were not disclosed.